ncRNA-Mediated High Expression of LPCAT1 Correlates with Poor Prognosis and Tumor Immune Infiltration of Liver Hepatocellular Carcinoma by Qiu Sun, Xudong Liu, Qunlong Peng, Lei Hu, Xiaochun Jiang

“…In this study, expression analysis and survival analysis for LPCAT1 in pan cancers were first performed by using The Cancer Genome Atlas (TCGA) data, which suggested that LPCAT1 might be a potential LIHC oncogene. Then, ncRNAs contributing to the overexpression of LPCAT1 were explored in starBase by a combination of expression analysis, correlation analysis, and survival analysis. …”
Get full text

PRMT6 promotes colorectal cancer progress via activating MYC signaling by Xin Zhang, Mingxin Jin, Yali Chu, Fengjun Liu, Hui Qu, Cheng Chen

“…This study investigates the role of protein arginine methyltransferase 6 (PRMT6) as an oncogene in CRC and its mechanistic involvement in tumor progression. …”
Get full text

In vivo trafficking of cancer-derived exosomes and their role in metastasis by Shih-Yen Wei, Sarah E. Shelton, Ying-Chieh Chen, Ke Huang

“…This process is driven by a combination of biological processes including invasion, intravasation, circulation, extravasation, and colonization of distant organs, among which cancer cell-derived exosomes facilitate metastasis through their enriched oncogenic miRNAs and lncRNAs to enhance cancer cell migration and invasion, promote epithelial-mesenchymal transition in recipient cells, help cancer cells evade immune detection, and alter the microenvironment to promote the formation of a pre-metastatic niche. …”
Get full text

Human Papillomavirus Detection in Head and Neck Squamous Cell Carcinomas at a Tertiary Hospital in Sub-Saharan Africa by Evans Aboagye, Francis Agyemang-Yeboah, Babatunde Moses Duduyemi, Christian Obirikorang

“…HPV was prevalent in 50% of oropharyngeal cancers, 27% of laryngeal cancers, and 23% of oral cavity cancers. HPV E6/E7 oncogenic DNA was found in 18% of the HNSCC cases, with HPV-16 being the predominant genotype present. …”
Get full text

Pancreatic Cancer: What the Oncologist Can Offer for Palliation by Malcolm J Moore

“…Some novel biological agents, including angiogenesis inhibitors, matrix metalloproteinase inhibitors, antisense compounds, inhibitors of cell signalling such as epidermal growth factor and vascular endothelial growth factor, and inhibitors of oncogene activation, are undergoing phase II and III trials in patients with pancreatic cancer. …”
Get full text

The Importance of CD44 as a Stem Cell Biomarker and Therapeutic Target in Cancer by Ranjeeta Thapa, George D. Wilson

“…Thus, this paper briefly focuses on the association of the major CD44 variant isoforms in cancer progression, the role of HA-CD44 interaction in oncogenic pathways, and strategies to target CD44-overexpressed tumor cells.…”
Get full text

Recent advances of antibody-drug conjugates in treating breast cancer with different HER2 status by Yue Qiu, Yaqin Shi, Zhujun Chao, Xinyu Zhu, Yan Chen, Linlin Lu

“…The identification of human epidermal growth factor receptor 2 (HER2) as an oncogenic driver in a subset of breast cancers, alongside the development of HER2-targeted therapies, has significantly improved the prognosis of HER2-amplified breast cancers. …”
Get full text

A review on the potential of Bruton’s tyrosine kinase (Btk) inhibitor – Ibrutinib for treatment of Multiple Myeloma (MM) by Sze-Ting Bong, Lydia Ngiik-Shiew Law, Jodi Woan-Fei Law

“…However, there is limited evidence on the Btk mechanisms involved in MM, hence, it is important to further investigate the Btk oncogenic signalling pathway(s) in MM cells in order to establish successful and improved treatment of MM. …”
Get full text

Genetic Alterations in Presumptive Precursor Lesions of Breast Carcinomas by Michaela Aubele, Martin Werner, Heinz Höfler

“…Using immuno‐histochemistry overexpression of the c‐erbB‐2 oncogene was found in ductal carcinoma in situ(DCIS), but not in atypical intraductal hyperplasia (AIDH) and intraductal hyperplasia (IDH). …”
Get full text

CD36 enrichment in HER2-positive mesenchymal stem cells drives therapy refractoriness in breast cancer by Lorenzo Castagnoli, Alma Franceschini, Valeria Cancila, Matteo Dugo, Martina Bigliardi, Claudia Chiodoni, Paolo Toneguzzo, Viola Regondi, Paola A. Corsetto, Filippo Pietrantonio, Serena Mazzucchelli, Fabio Corsi, Antonio Belfiore, Antonio Vingiani, Giancarlo Pruneri, Francesca Ligorio, Mario P. Colombo, Elda Tagliabue, Claudio Tripodo, Claudio Vernieri, Tiziana Triulzi, Serenella M. Pupa

“…Conclusions These results support the metabolo-oncogenic nature of CD36-mediated FA uptake in HER2 + therapy-refractory BC. …”
Get full text

Hypoxia-induced circPLOD2a/b promotes the aggressiveness of glioblastoma by suppressing XIRP1 through binding to HuR by Aixin Yu, Yiqi Wang, Chao Duan, Jun Qin, Miaomiao Liao, Haiyan Zhu, Junrong Lei, Jun Liu, Zehao Yang, Li Yu, Hui Gui, Jinxin Xin, Weiwei Tao, Wendai Bao, Zhiqiang Dong

“…In conclusion, hypoxia-induced circPLOD2a and b are oncogenic regulators of tumour aggressiveness through attenuating the interaction between HuR and XIRP1 in glioblastoma cells and may be potential therapeutic targets for this disease.…”
Get full text

Cyclin E1/CDK2 activation defines a key vulnerability to WEE1 kinase inhibition in gynecological cancers by Daehwan Kim, Heekyung Chung, Wen Liu, Kangjin Jeong, Tugba Y. Ozmen, Furkan Ozmen, Matthew J. Rames, Sangyub Kim, Xiao Guo, Nathan Jameson, Petrus R. de Jong, Steven Yea, Laurie Harford, Jiali Li, Cara A. Mathews, Deborah B. Doroshow, Vincent J. Charles, Doris Kim, Kimberlee Fischer, Ahmed A. Samatar, Adrian Jubb, Kevin D. Bunker, Kimberly Blackwell, Fiona Simpkins, Funda Meric-Bernstam, Gordon B. Mills, Olivier Harismendy, Jianhui Ma, Mark R. Lackner

“…Abstract Upregulation of Cyclin E1 and subsequent activation of CDK2 accelerates cell cycle progression from G1 to S phase and is a common oncogenic driver in gynecological malignancies. WEE1 kinase counteracts the effects of Cyclin E1/CDK2 activation by regulating multiple cell cycle checkpoints. …”
Get full text

Mechanisms and technologies in cancer epigenetics by Zaki A. Sherif, Olorunseun O. Ogunwobi, Habtom W. Ressom

“…We navigate through the tumultuous seas of epigenetic dysregulation, exploring how these processes conspire to silence tumor suppressors and unleash oncogenic potential. The narrative pivots to cutting-edge technologies, revolutionizing our ability to decode the epigenome. …”
Get full text

KRASG12C‐inhibitor‐based combination therapies for pancreatic cancer: insights from drug screening by Constanza Tapia Contreras, Jonas Dominik Falke, Dana‐Magdalena Seifert, Carolin Schneider, Lukas Krauß, Xin Fang, Denise Müller, Engin Demirdizen, Melanie Spitzner, Tiago De Oliveira, Christian Schneeweis, Jochen Gaedcke, Silke Kaulfuß, Kimia Mirzakhani, Bernd Wollnik, Karly Conrads, Tim Beißbarth, Gabriela Salinas, Jonas Hügel, Nils Beyer, Sophia Rheinländer, Ulrich Sax, Matthias Wirth, Lena‐Christin Conradi, Maximilian Reichert, Volker Ellenrieder, Philipp Ströbel, Michael Ghadimi, Marian Grade, Dieter Saur, Elisabeth Hessmann, Günter Schneider

“…The predominant driver in PDAC is mutated KRAS proto‐oncogene, KRA, present in 90% of patients. The emergence of direct KRAS inhibitors presents a promising avenue for treatment, particularly those targeting the KRASG12C mutated allele, which show encouraging results in clinical trials. …”
Get full text

Direct Reprogramming of Mouse Fibroblasts to Neural Stem Cells by Small Molecules by Yan-Chuang Han, Yoon Lim, Michael D. Duffieldl, Hua Li, Jia Liu, Nimshitha Pavathuparambil Abdul Manaph, Miao Yang, Damien J. Keating, Xin-Fu Zhou

“…Such chemical induction removes the risks associated with current techniques such as the use of viral vectors or the induction of oncogenic factors. This technique may, therefore, enable NSC to be utilized in various applications within clinical medicine.…”
Get full text

Comparison of differences in transcriptional and genetic profiles between intra-central nervous system and extra-central nervous system large B-cell lymphoma by Shu Wang, Hong Chen, Bo Dai, Kang Zheng, Jiajun Zheng, Yuqi Zhu, Yan Yuan, Tianling Ding, Qian Wang, Liqian Xie, Rui Feng, Fengping Zhu, Jianbin Xiang, Weiqun Ding, Hong Ding, Yuan Li, Xiaodong Gu, Kunpeng Wu, Yifan Yuan, Jianping Song, Dongxiao Zhuang, Haoshu Zhong, Hanfeng Wu, Ying Mao, Tong Chen

“…In summary, our study provides comprehensive insights into the transcriptomic and genetic characteristics of PCNS-DLBCL in contrast to ecDLBCL and will help dissect the oncogenic mechanism of this disease.…”
Get full text

Synergistic effect of inhibiting CHK2 and DNA replication on cancer cell growth by Flavie Coquel, Sing-Zong Ho, Keng-Chang Tsai, Chun-Yen Yang, Antoine Aze, Julie Devin, Ting-Hsiang Chang, Marie Kong-Hap, Audrey Bioteau, Jerome Moreaux, Domenico Maiorano, Philippe Pourquier, Wen-Chin Yang, Yea-Lih Lin, Philippe Pasero

“…Cancer cells display high levels of oncogene-induced replication stress (RS) and rely on DNA damage checkpoint for viability. …”
Get full text

NVP-2, in combination with Orlistat, represents a promising therapeutic strategy for acute myeloid leukemia by Qing Zhu, Jia Cheng, Yuqing Gao, Zimu Zhang, Jian Pan, Xin Su, Danhong Fei, Linbo Cai, Juanjuan Yu, Yanling Chen, Wanyan Jiao, Di Wu, Xiaolu Li, Peifang Xiao

“…CDK9, a kinase that regulates gene transcription and cell cycle, also induces oncogene transcription and abnormal cell cycle in AML cells. …”
Get full text

Expression Levels of Some Antioxidant and Epidermal Growth Factor Receptor Genes in Patients with Early-Stage Non-Small Cell Lung Cancer by Giuseppe De Palma, Paola Mozzoni, Olga Acampa, Eveline Internullo, Paolo Carbognani, Michele Rusca, Matteo Goldoni, Massimo Corradi, Marcello Tiseo, Pietro Apostoli, Antonio Mutti

“…Antioxidant genes included heme oxygenase 1 (HO-1), superoxide dismutase-1 (SOD-1), and -2 (SOD-2), whereas epidermal growth factor receptor genes consisted of epidermal growth factor receptor (EGFR) and v-erb-b2 erythroblastic leukaemia viral oncogene homolog 2 (HER-2). Twenty-eight couples of lung biopsies were obtained and gene transcripts were quantified by Real Time RT-PCR. …”
Get full text

Role of silent mutations in KRAS-mutant tumors by Jun Lu, Chao Zhou, Feng Pan, Hongyu Liu, Haohua Jiang, Hua Zhong, Baohui Han, Xiangxiang Pan

“…Kirsten-RAS (KRAS) mutations, predominantly oncogenic, are pivotal drivers in various cancers. …”
Get full text